solanezumab
Jump to navigation
Jump to search
Indications
- none
Contraindications
- treatment of Alzheimer's disease
Dosage
Mechanism of action
- immunoglobulin G1 monoclonal antibody that binds to the mid-domain of the beta-amyloid monomer
Clinical trials
- solanezumab failed to improve cognitive function in patients with mild to moderate Alzheimer's disease[3]
- tested in dominantly inherited Alzheimer's disease with average follow up of 5 years.[4]
- does not slow cognitive decline in symptomatic patients or show benefit in Alzheimer markers
- does not slow cognitive decline in preclinical Alzheimer's disease[5]
- did not result in clearance of brain amyloid plaque[6]
More general terms
Additional terms
References
- ↑ Doody RS et al Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. N Engl J Med 2014; 370:311-321. January 23, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24450890 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1312889
- ↑ Sacks CA, Avorn J, Kesselheim AS The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. N Engl J Med 2017; 376:1706-1708. May 4, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28467878 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMp1701047?query=aging-geriatrics
- ↑ 3.0 3.1 Honig LS, Vellas B, Woodward M et al Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med 2018; 378:321-330. Jan 25, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29365294 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1705971
- ↑ 4.0 4.1 George J Investigational Alzheimer's Drug Shows Effects in Inherited Early-Onset Disease MedPage Today June 21,2021 https://www.medpagetoday.com/neurology/alzheimersdisease/93193
Salloway S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease Nature Medicine (2021) PMID: https://www.ncbi.nlm.nih.gov/pubmed/34155411 https://www.nature.com/articles/s41591-021-01369-8 - ↑ 5.0 5.1 5.2 Sperling RA et al. Trial of solanezumab in preclinical Alzheimer's disease. N Engl J Med 2023 Jul 17; PMID: https://www.ncbi.nlm.nih.gov/pubmed/37458272 https://www.nejm.org/doi/10.1056/NEJMoa2305032
- ↑ 6.0 6.1 Lilly March 8, 2023 Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease. https://investor.lilly.com/node/48566/pdf